MARÍA PILAR
GARCÍA ALFONSO
Profesora asociada de Ciencias de la Salud
Instituto de Investigación Sanitaria Gregorio Marañón
Madrid, EspañaPublications in collaboration with researchers from Instituto de Investigación Sanitaria Gregorio Marañón (11)
2024
2023
-
An international comparative analysis and roadmap to sustainable biosimilar markets
Frontiers in Pharmacology, Vol. 14
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
The Lancet, Vol. 402, Núm. 10395, pp. 41-53
-
Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3378-3394
2021
-
Biomarkers associated with regorafenib first-line treatment benefits in metastatic colorectal cancer patients: Reframe molecular study
Cancers, Vol. 13, Núm. 7
-
Dpyd exome, mrna expression and uracil levels in early severe toxicity to fluoropyrimidines: An extreme phenotype approach
Journal of Personalized Medicine, Vol. 11, Núm. 8
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
2020
-
Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status
Clinical and Translational Oncology, Vol. 22, Núm. 11, pp. 2026-2031
2014
-
Validaciónde polimorfismos genéticos asociados a toxicidad al tratamiento quimioteŕapico en pacientes de cancer colorrectal
Farmacia Hospitalaria, Vol. 38, Núm. 4, pp. 283-290
2013
-
Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer
Cancer Chemotherapy and Pharmacology, Vol. 71, Núm. 6, pp. 1463-1472
-
Erratum: Differential toxicity biomarkers for irinotecan and oxaliplatin containing chemotherapy in colorectal cancer (Cancer Chemotherapy and Pharmacology (2013) 71 (1463-1472) DOI: 10.1007/s00280-013-2145-6)
Cancer Chemotherapy and Pharmacology